Pharmacodynamic results demonstrated that the mouse model of hyperlipidemia was successfully established by HFD, and the metabolic protective effect could be improved by SM treatment, including reducing fat accumulation, decreasing blood glucose level, improving insulin sensitivity, and protecting liver function. Here, INS is linked to hyperlipidemia.